Turkey 2017 Clinical Practice Guidelines on recommendations for screning diagnosing and managing hepatitis C virus
| العنوان: | Turkey 2017 Clinical Practice Guidelines on recommendations for screning diagnosing and managing hepatitis C virus |
|---|---|
| المؤلفون: | Ramazan Idilman, Nurcan Baykam, Sabahattin Kaymakoglu, Fehmi Tabak, Halil I. Bahcecioglu, Ahmet Bektas, Cemal Bulut, Fulya Gunsar, Dilara Inan, Hayat K. Karaosmanoglu, Zeki Karasu, Ferit Kuscu, Birgul Mete, Omer Ozbakir, Osman C. Ozdogan, Mehmet Parlak, Fatma Sirmatel, Omer Topalak, Belkis Unsal, Viral Hepatitis Guidelines Study Group |
| المصدر: | The Turkish Journal of Gastroenterology. 28:90-93 |
| بيانات النشر: | AVES Publishing Co., 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Liver Cirrhosis, 0301 basic medicine, medicine.medical_specialty, Turkey, Turkish, Hepatitis C virus, Hepacivirus, medicine.disease_cause, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Liver Function Tests, medicine, Humans, In patient, business.industry, Optimal treatment, Gastroenterology, Disease Management, Guideline, medicine.disease, Hepatitis C, language.human_language, Clinical Practice, Regimen, 030104 developmental biology, 030220 oncology & carcinogenesis, Family medicine, language, business, Viral hepatitis |
| الوصف: | The present guideline updates the Turkish recommendations for the screening, diagnosis and management of Hepatitis C virus (HCV) infection prepared by the Turkish Association for the Study of the Liver (TASL) and Viral Hepatitis Society (VHS). The aim of this guidance was to provide updates recommendations to physicians, who are interested in HCV care on the optimal screening, diagnosis and pre-treatment management for patients with HCV infection in Turkey. These recommendations, produced by panel experts, were aimed to addresses the management issues ranging from diagnosis and linkage to care, to the optimal treatment regimen in patients with HCV infection. Recommendations are based on evidence and opinions of more than 70% of the panelists. This guidance is supported by the memberships of two societies and not by pharmaceutical companies. This guidance will be updated frequently as new data become available. |
| تدمد: | 2148-5607 1300-4948 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071976ae280166d96841d5f0fe192c72 https://doi.org/10.5152/tjg.2017.21 |
| رقم الأكسشن: | edsair.doi.dedup.....071976ae280166d96841d5f0fe192c72 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21485607 13004948 |
|---|